Human Pathology
Volume 41, Issue 3 , Pages 343-351 , March 2010

Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma

  • Suguru Matsuura, MD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Yoshinao Oda, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors. Yoshinao Oda is to be contacted at Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Masazumi Tsuneyoshi, Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
    • ,
  • Hiroshi Matono, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Teiyu Izumi, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Hidetaka Yamamoto, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Sadafumi Tamiya, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Yukihide Iwamoto, MD, PhD

      Affiliations

    • Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Masazumi Tsuneyoshi, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors. Yoshinao Oda is to be contacted at Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Masazumi Tsuneyoshi, Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Received 22 April 2009 ,Revised 27 July 2009 ,Accepted 10 August 2009.

References 

  1. Jodel S, Blavier L, Yoon JM, et al. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006;25:35–43
  2. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98:621–628
  3. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003;17:7–30
  4. Tousseyen T, Jonissen E, Reiss K, et al. (Make) stick and cut loose—disintegrin metalloproteases in development and disease. Birth Defects Res C Embryo Today. 2006;78:24–46
  5. Frolich C, Albrechtsen R, Dyrskjot L, et al. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res. 2006;12:7359–7368
  6. Rocks N, Paulissen G, Quesasa CF, et al. Expression of A disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer. 2006;94:724–730
  7. Carl-McGrath S, Lendeckel U, Ebert M, et al. The disintegrin-metalloproteases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17–24
  8. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37–43
  9. Sakamoto A, Oda Y, Iwamoto Y, et al. Expression of membrane type 1 matrix metalloprotease, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol. 1999;125:541–548
  10. Hackel CG, Krueger S, Grote HJ, et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer. 2000;89:995–1003
  11. Zyada MM, Shamaa AA. Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness. Diagn Pathol. 2008;13:3–26
  12. Bjornsson J, McLeod RA, Unni KK. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83:2105–2119
  13. Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190–4196
  14. Zhao Z, Wen LY, Jin M, et al. ADAM28 participates in the regulation of tooth development. Arch Oral Biol. 2006;51:996–1005
  15. Kalinski T, Krueger S, Sel S, et al. ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma. Hum Pathol. 2007;38:86–94
  16. Romeo S, Bovée JV, Jadnanansing NA, et al. Expression of cartilage growth plate signalling molecules in chondroblastoma. J Pathol. 2004;202:113–120
  17. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765–27767
  18. Schwettmann L, Wehmeier M, Jokovic D, et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol. 2008;49:243–250
  19. Okada A, Mochizuki S, Yatabe T, et al. ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis Rheum. 2008;58:778–789
  20. Mckie N, Edwards T, Dallas DJ, et al. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem Biophys Res Commun. 1997;230:335–339
  21. Flannery CR, Little CB, Caterson B, et al. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. 1999;18:225–237
  22. Kveiborg M, Albrechtsen R, Rudkjaer L, et al. ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation. J Bone Miner Res. 2006;21:1288–1296
  23. Mitsui Y, Mochizuki S, Kodama T, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66:9913–9920
  24. McGowan PM, Duffy MJ. Matrix metalloprotease expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008;19:1566–1572
  25. Heist RS, Marshall AL, Liu G, et al. Matrix mealloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res. 2006;12:5448–5453
  26. Jones LE, Humphreys MJ, Campbell F, et al. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res. 2004;10:2832–2845
  27. Kawashima A, Okada Y, Nakanishi I, et al. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol. 1997;142:129–137
  28. Uria JA, Balbin M, Lopez JM, et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol. 1998;153:91–101
  29. Müller S, Söder S, Oliveira AM, et al. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton. Mod Pathol. 2005;18:1088–1094
  30. Ayala G, Liu C, Nicosia R, et al. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol. 2000;31:341–346
  31. Bovée JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189:454–462
  32. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106:2682–2691
  33. Huang L, Cheng YY, Chow LT, et al. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol. 2003;56:116–120

☆ This work was supported by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (18590332), Tokyo, Japan.

PII: S0046-8177(09)00288-3

doi: 10.1016/j.humpath.2009.08.002

Human Pathology
Volume 41, Issue 3 , Pages 343-351 , March 2010

Article Tools

* Image Usage & Resolution